ADME

BioIVT to Host Symposium and Workshop in Brussels on Advanced In Vitro ADME Methodologies

Retrieved on: 
Tuesday, April 9, 2024
Molecule, AME Publishing Company, Development, Hepatocyte, Application, Travel, Running, Doctor of Philosophy, Senior, University of Oxford, ADME, Drug development, MPS

WESTBURY, N.Y., April 9, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host Small Molecules and Biologics: Advanced ADME Strategies & Techniques, a complimentary symposium and workshop on methodologies and techniques for in vitro ADME research. Hosted at BioIVT's office and laboratory in Brussels, this two-day event will take place from April 11-12 and feature speakers from industry, academia and BioIVT. The workshop will include workstations for attendees to see product demonstrations and talk to BioIVT product experts about how these products can be used in their research applications. Please visit BioIVT's website for registration and additional details here. 

Key Points: 
  • WESTBURY, N.Y., April 9, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host Small Molecules and Biologics: Advanced ADME Strategies & Techniques , a complimentary symposium and workshop on methodologies and techniques for in vitro ADME research.
  • Hosted at BioIVT's office and laboratory in Brussels, this two-day event will take place from April 11-12 and feature speakers from industry, academia and BioIVT.
  • The workshop will include workstations for attendees to see product demonstrations and talk to BioIVT product experts about how these products can be used in their research applications.
  • In addition to being the largest supplier of products for in vitro ADME studies, the company also will discuss the preclinical research services it offers, including designing and implementing in vitro ADME-Tox programs.

Eurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary Datasets

Retrieved on: 
Thursday, February 29, 2024
Health Technology, Data Management, Other Health, Technology, Pharmaceutical, Apps, Applications, Biometrics, Medical Devices, Artificial Intelligence, Other Technology, Biotechnology, Science, Software, Other Science, Research, Health, ADMET, Artificial intelligence, ADME, Machine learning, Phi coefficient, Absorption, Drug discovery, Metabolism, Suite

Eurofins Discovery , an industry-leading provider of products and services for drug discovery research, today announced the launch of DiscoveryAI SAFIRE (Suite of ADMET Predictions For In Silico Refinement and Evaluation).

Key Points: 
  • Eurofins Discovery , an industry-leading provider of products and services for drug discovery research, today announced the launch of DiscoveryAI SAFIRE (Suite of ADMET Predictions For In Silico Refinement and Evaluation).
  • SAFIRE is an advanced platform that leverages proprietary datasets, artificial intelligence (AI), and machine learning (ML), offering a unique capability for expediting discovery.
  • It’s proven effective in accelerating drug discovery projects from initial hit discovery through to lead optimization.
  • For more details about SAFIRE’s benefits and significant value to the drug discovery community, visit eurofinsdiscovery.com/safire .

BioIVT to Showcase Leading Products for Toxicological Studies at the SOT ToxExpo 2024

Retrieved on: 
Thursday, March 7, 2024
Metabolism, SOT, Doctor of Philosophy, Research, Prodrug, Drug development, DDI, Society of Toxicology, Hall, Immune system, Learning, Cell, Poster, CES, Biotransformation, ADME, Medical device

WESTBURY, N.Y., March 7, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence and scientific contributions at the 2024 Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo .

Key Points: 
  • WESTBURY, N.Y., March 7, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence and scientific contributions at the 2024 Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo .
  • "The BioIVT team attending SOT includes experts from across our product portfolios.
  • We look forward to meeting with research colleagues and learning how we can support their programs," he added.
  • Visit BioIVT on the show floor at booth #1509 or schedule a time to connect with us and learn more: https://bioivt.com/about/events?entry=SOT+ToxExpo+2024

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Wednesday, February 7, 2024
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, B cell, Chronic obstructive pulmonary disease, Pharmacokinetics, KIT, HCV, Patient, Safety, Heart, Drug discovery, Virology, Fiscal, Disease, CSU, ADME, RSV, Sale, OMERS, Viral load, Medication, Asthma, Conference, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended December 31, 2023.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended December 31, 2023.
  • “In 2024, Enanta began a year which will be marked by execution and value creation across the company.
  • For the three months ended December 31, 2022, total revenue was $23.6 million and was primarily related to royalties on AbbVie’s sales of MAVYRET®/MAVIRET®.
  • Interest expense from the royalty sale was $3.4 million for the three months ended December 31, 2023.

Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations

Retrieved on: 
Thursday, February 1, 2024
Met, Pharmacokinetics, Growth, Peptide, Absorption, Pharmacology, Immunohistochemistry, Safety, IDD, TK, Appetite, Drug discovery, Proteolysis targeting chimera, DMPK, Automation, ADME, Metabolite, Metabolism, Toxicology, Development, Biology

HYDERABAD, India, Feb. 01, 2024 (GLOBE NEWSWIRE) -- To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , has expanded its DMPK capabilities .

Key Points: 
  • HYDERABAD, India, Feb. 01, 2024 (GLOBE NEWSWIRE) -- To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , has expanded its DMPK capabilities .
  • Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “The focus of innovator companies on diversifying their supply chains bodes well for Indian CROs-CDMOs like ours.
  • Sauri Gudlavalleti, Chief Operating Officer said, “The latest expansion of DMPK capabilities augments our integrated drug discovery (IDD) offerings.
  • Sai Life Sciences also has plans to invest in niche areas such as peptides, oligos and large molecules to strengthen its discovery capabilities.

In Vitro Toxicology Testing Market Research Report 2023 - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 23, 2024
Science, Other Science, Research, Pharmaceutical, Health, Cosmetics, Retail, Other Health, European, Toxicology, Food, Animal, ELISA, Equipment, ADME, Drug discovery, Investment, USD, Patent, Consumables, Growth, Medical device

The "In Vitro Toxicology Testing Market by Product & Service (Assays (ELISA & Western Blot), Equipment, Consumable, Software), Toxicity Endpoints (ADME, Genotoxicity, Cytotoxicity), Technology, Method, Industry (Pharma, Cosmetics) - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In Vitro Toxicology Testing Market by Product & Service (Assays (ELISA & Western Blot), Equipment, Consumable, Software), Toxicity Endpoints (ADME, Genotoxicity, Cytotoxicity), Technology, Method, Industry (Pharma, Cosmetics) - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • In 2022, the consumables segment accounted for the largest share of products & services in the global In vitro toxicology testing market.
  • Furthermore, the market share of the consumables market is expected to grow simultaneously with the increasing adoption of in vitro toxicology testing across various industries.
  • Europe has continued to dominate the in vitro toxicology testing market during the forecast period of 2023-2028.

CN Bio and Altis Biosystems Partner to Develop Next-generation Human Gut/Liver in vitro model for Advanced ADME Studies

Retrieved on: 
Tuesday, January 23, 2024
Health, Health Technology, Other Science, Research, Science, Pharmaceutical, Biotechnology, Pharmacy, Animal, Partnership, Nature Reviews Drug Discovery, MPS, Olympia, Greece, ADME, Absorption, Drug discovery, Drug development, System, Metabolism, Pharmacokinetics, Pharmaceutical industry

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

Key Points: 
  • CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.
  • CN Bio and Altis’ integrated Gut/Liver MPS bridges this gap for more accurate predictions of human drug oral bioavailability earlier in the drug development process.
  • Primary human cells are considered the gold standard for advanced in vitro models; however, gut cells present challenges that limit their use.
  • By interconnecting the RepliGut Planar-Jejunum model with CN Bio’s industry-leading primary human Liver-on-a-Chip, the dual-organ Gut/Liver model represents the next-generation of CN Bio’s oral bioavailability assay.

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Virology, Conference, Heart, Partnership, RSV, FDA, Medication, Chronic obstructive pulmonary disease, Disease, Hepatitis, KIT, Viral load, ADME, Pharmacokinetics, Asthma, COVID-19, CSU, Webcast, Patient, Safety, Therapy, Fast Track, Pharmaceutical industry

Our foundational capabilities in virology and small molecule drug development transition well to immunology, an adjacent field where we can leverage our core strengths.

Key Points: 
  • Our foundational capabilities in virology and small molecule drug development transition well to immunology, an adjacent field where we can leverage our core strengths.
  • The company has developed novel, potent and selective oral inhibitors of KIT, which are now being optimized in preclinical development.
  • Enanta will present new preclinical data on its prototype KIT inhibitor at the J.P. Morgan Conference and is targeting the selection of a development candidate in 2024.
  • A replay of the webcast will be available following the presentation and will be archived for approximately 60 days.

DeepMirror Launches Early Access Programme for Its Intuitive Molecular Drug Design Software

Retrieved on: 
Monday, December 11, 2023
University, Biotechnology, Education, Technology, Health, Pharmaceutical, Health Technology, Research, Software, Artificial Intelligence, Science, BCG, DMTA, Trust, Medicinal chemistry, ISCB Senior Scientist Award, University of Cambridge, Wellcome Trust, Entrepreneurship, Toxicity, Drug design, System, AI, ADME, Lead, Access, Medical device, Drug discovery

DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, today announced the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months.

Key Points: 
  • DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, today announced the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months.
  • The software allows users to tap into AI-driven insights to improve and accelerate molecular design across the drug discovery pipeline through a secure and user-friendly interface which makes AI-powered drug discovery as simple as using a spreadsheet.
  • AI-enabled drug discovery programmes often start with pharmaceutical companies partnering with AI companies to deliver insights for their drug discovery efforts.
  • After 12 months of development and a successful beta testing programme, we are excited to officially launch DeepMirror to early adopters.

Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

Retrieved on: 
Monday, November 13, 2023
Software, Research, General Health, Pharmaceutical, Oncology, Medical Devices, Technology, Artificial Intelligence, Science, Biotechnology, Neurology, Health, World Health Organization, Multiple myeloma, NYSE, Causal AI, Prevalence, Biology, PDX, Digital twin, IND, WHO, HD, PD, Multimedia, Prostate cancer, Pharmacology, Therapy, Dementia, Drug discovery, Neurodegenerative disease, CRL, Cancer, Partnership, Biomarker, AI, ADME, HIV disease progression rates, DSM-IV codes, Pharmaceutical industry, Medical imaging, Causality (physics), Logica

Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia , a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™ , Charles River’s Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia , a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™ , Charles River’s Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
  • There are currently no known cures for these diseases, and the prevalence of all three diseases rises year-over-year.
  • As part of the partnership, Charles River has made an equity investment in Aitia.
  • More recently, Charles River and Related Sciences announced a multi-program collaboration to apply Logica across several previously undrugged targets.